Biohaven Just Hurdled An FDA Setback — And Its Moving Lines

cafead

Administrator
Staff member
  • cafead   Feb 11, 2025 at 09:52: PM
via Biohaven (BHVN) stock hurdled its 50-day and 200-day lines Tuesday after the Food and Drug Administration granted its spinocerebellar ataxia treatment a speedier review time.

article source